AngioDynamics Comments on Patent Infringement Lawsuit Related To ELVS.Business Editors QUEENSBURY, N.Y.--(BUSINESS WIRE)--Jan. 23, 2004 AngioDynamics, Inc., a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of E-Z-EM, Inc. (AMEX AMEX See: American Stock Exchange :EZM), today announced that Diomed, Inc., a subsidiary of Diomed Holdings, Inc., has filed a lawsuit against the Company in the federal district court in Massachusetts alleging patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. related to AngioDynamics' ELVS ELVS E-Learning in the Voluntary Sector ELVS Electro-Magnetic Log Voltage Simulator (TM) endovascular laser venous system. This system is used for the treatment of severe varicose veins. The suit involves a single patent, Number 6,398,777, covering the endovascular laser treatment of varicose veins. "The Company has analyzed the Diomed patent, and has a written opinion of non-infringement from outside patent counsel," said Eamonn Hobbs, president and chief executive officer of AngioDynamics. "We believe our ELVS product does not infringe the Diomed patent, and we intend to vigorously defend this action." About ELVS The ELVS(TM) endovascular laser venous system is a patient friendly, minimally invasive alternative for the treatment of severe varicose veins. The ELVS procedure, which lasts about 45 minutes, offers patients an effective out-patient alternative to surgical ligation ligation /li·ga·tion/ (li-ga´shun) the application of a ligature. tubal ligation sterilization of the female by constricting, severing, or crushing the uterine tubes. and vein stripping. The Company markets and sells the ELVS system throughout the United States. About AngioDynamics AngioDynamics, Inc. (www.angiodynamics.com) is a leading supplier of products used by interventional radiologists and other physicians for the minimally invasive diagnosis and therapeutic treatment of peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. . About E-Z-EM E-Z-EM, Inc. (www.ezem.com) is a leading supplier of products used by radiologists, gastroenterologists and speech language pathologists for the diagnostic imaging of diseases and disorders of the GI tract, ranging from swallowing disorders (dysphagia dysphagia /dys·pha·gia/ (-fa´jah) difficulty in swallowing. dys·pha·gia or dys·pha·gy n. Difficulty in swallowing or inability to swallow. ) to colorectal cancers. E-Z-EM also is a third-party contract manufacturer of diagnostic contrast media, pharmaceuticals, non-prescription healthcare products, and defense decontaminants. ELVS is a trademark of Biolitec Inc. The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the outcome of the Diomed patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended November 29, 2003, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion